Comparison of three different methods for measurement of cervical cord atrophy in multiple sclerosis

American Journal of Neuroradiology

Volumn 29, Issue 2, 2008, Pages 319-325

  Zivadinov, Robert ^a,b   Banas, A C ^a   Yella, V ^b   Abdelrahman, N ^b   Weinstock Guttman, B ^a   Dwyer, M G ^b  

^a JACOBS NEUROLOGICAL INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CERVICAL SPINAL CORD; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; REPRODUCIBILITY; SPINAL CORD ATROPHY; STATISTICAL ANALYSIS;

ADULT; ATROPHY; CERVICAL VERTEBRAE; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPINAL CORD;

EID: 39649105254     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A0813     Document Type: Article

References (43)

1. Zivadinov R, Leist TP. Clinical-magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging 2005;15:10S-21S
2. Tench CR, Morgan PS, Jaspan T, et al. Spinal cord imaging in multiple sclerosis. J Neuroimaging 2005;15:94S-102S
3. Rocca MA, Hickman SJ, Bo L, et al. Imaging spinal cord damage in multiple sclerosis. J Neuroimaging 2005;15:297-304
4. Thorpe JW, Kidd D, Moseley IF, et al. Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. Brain 1996;119:709-14
5. Kidd D, Thorpe JW, Kendall BE, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:15-19
6. Lycklania a Nijeholt GJ, Uitdehaag BM, Bergers E, et al. Spinal cord magnetic resonance imaging in suspected multiple sclerosis. Eur Radiol 2000;10:368-76
7. Rocca MA, Mastronardo G, Horsfield MA, et al. Comparison of three MR sequences for the detection of cervical cord lesions in patients with multiple sclerosis. AJNR Am J Neuroradiol 1999;20:1710-16
8. Campi A, Pontesilli S, Gerevini S, et al. Comparison of MRI pulse sequences for investigation of lesions of the cervical spinal cord. Neuroradiology 2000;42:669-75
9. Nijeholt GJ, van Walderveen MA, Castejijns JA, et al. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain 1998;121:687-97
10. Losseff NA, Miller DH. Measures of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64(suppl 1):S102-05
11. Filippi M, Campi A, Martinelli V, et al. Brain and spinal cord MR in benign multiple sclerosis: a follow-up study. J Neurol Sci 1996;143:143-49
12. Lovas G, Szilagyi N, Majtenyi K, et al. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 2000;123:308-17
13. DeLuca GC, Ebers GC, Esiri MM. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 2004;127:1009-18
14. Davie CA, Barker GJ, Webb S, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995;118:1583-92
15. Stevenson VL, Leary SM, Losseff NA, et al. Spinal cord atrophy and disability in MS: a longitudinal study. Neurology 1998;51:234-38
16. Trapp BD, Peterson J, Ransohoff, RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-85
17. Trop I, Bourgouin PM, Lapierre Y, et al. Multiple sclerosis of the spinal cord: diagnosis and follow-up with contrast-enhanced MR and correlation with clinical activity. AJNR Am J Neuroradiol 1998;19:1025-33
18. Kidd D, Thorpe FW, Thompson AJ, et al. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 1993;43:2632-37
19. Ingle GT, Stevenson VL, Miller DH, et al. Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain 2003;126:2528-36
20. Lin X, Tench CR, Turner B, et al. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial. J Neurol Neurosurg Psychiatry 2003;74:1090-94
21. Losseff NA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;119:701-08
22. Lin X, Tench CR, Evangelou N, et al. Measurement of spinal cord atrophy in multiple sclerosis. J Neuroimaging 2004;14:S20-26
23. Coulon O, Hickman SJ, Parker GJ, et al. Quantification of spinal cord atrophy from magnetic resonance images via a B-spline active surface model. Magn Reson Med 2002;47:1176-85
24. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-27
25. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
26. Canny J. A computational approach to edge detection. IEEE Trans 1986:679-98
27. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239-47
28. Zivadinov R, Sepcic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:773-80
29. Benedict RH, Bruce J, Dwyer MG, et al. Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Mult Scler 2007;13:722-30
30. Tavazzi E, Dwyer MG, Weinstock-Guttman B, et al. Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. Neuroimage 2007;36:746-54
31. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11
32. Tench CR, Constantinescu CS. Technical Aspects of Spinal Cord Atrophy Measurement. Hauppauge, NY: Nova Biomedical Books; 2004;63-72
33. Stevenson VL, Miller DH, Leary SM, et al. One year follow up study of primary and transitional progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;68:713-18
34. Rashid W, Davies GR, Chard DT, et al. Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study. J Neurol Neurosurg Psychiatry 2006;77:51-55
35. Horakova D, Cox JL, Havrdova E, et al. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years. A case control study. J Neurol Neurosurg Psychiatry 2007; [Epub ahead of print]
36. Benedict R, Bruce J, Dwyer M, et al. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol 2006;63:1301-06
37. Anderson VM, Fernando KT, Davies GR, et al. Cerebral atrophy measurement in clinically isolated syndromes and relapsing remitting multiple sclerosis: a comparison of registration-based methods. J Neuroimaging 2007;17:61-68
38. Rovaris M, Gass A, Bammer R, et al. Diffusion MRI in multiple sclerosis. Neurology 2005;65:1526-32
39. Lin X, Blumhardt LD, Constantinescu CS. The relationship of brain and cervical cord volume to disability in clinical subtypes of multiple sclerosis: a three-dimensional MRI study. Acta Neurol Scand 2003;108:401-06
40. Bot JC, Barkhof F, Polman CH, et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 2004;62:226-33
41. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-36
42. Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003;60:44-51
43. Kalkers NF, Barkhof F, Bergers E, et al. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler 2002;8:532-33